EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway

Jiageng Guo, Xinya Jiang, Jing Lian, Huaying Li, Fan Zhang, Jinling Xie, Jiagang Deng, Xiaotao Hou, Zhengcai Du, Erwei Hao

Frontiers in Cell and Developmental Biology · 02.08.2024 · 12

DOI: 10.3389/fcell.2024.1431423 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 02.08.2024. Verfasst von Jiageng Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, China. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K/AKT/GSK-3β signaling pathway plays a pivotal role in numerous physiological and pathological processes, including cell proliferation, apoptosis, differentiation, and metabolic regulation. Aberrant activation of the PI3K/AKT pathway is intricately linked to development of tumor. GSK-3β, belonging to the serine/threonine protein kinase family, is crucial in the pathogenesis of liver cancer. As a key rate-limiting enzyme in the glucose metabolism pathway, GSK-3β significantly impacts the growth, proliferation, metastasis, and apoptosis of liver cancer cells. It is also implicated in chemotherapy resistance. Elevated expression of GSK-3β diminishes the sensitivity of liver cancer cells to chemotherapeutic agents, thereby playing a substantial role in the development of drug resistance. Consequently, targeting of GSK-3β, particularly within the PI3K/AKT signaling pathway, is regarded as a promising therapeutic strategy for liver cancer. The precise identification and subsequent modulation of this pathway represent a substantial potential for innovative clinical interventions in the management of liver cancer.

Schlagwörter

Stichwörter der Autor:innen

GSK-3βPI3K/Akt pathwayliver cancerregulatory mechanismsignal transduction

Autor:innen und Institutionen

  • Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, China.
  • Guangxi Collaborative Innovation Center of Study on Functional Ingredients of Agricultural Residues, Guangxi University of Chinese Medicine, Nanning, China.
  • Guangxi Key Laboratory of TCM Formulas Theory and Transformation for Damp Diseases, Guangxi University of Chinese Medicine, Nanning, China.
  • Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China.

Zitieren

APA

Guo, J., Jiang, X., Lian, J., Li, H., Zhang, F., Xie, J., Deng, J., Hou, X., Du, Z., & Hao, E. (2024). Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1431423

Vancouver

Guo J, Jiang X, Lian J, Li H, Zhang F, Xie J, et al. Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1431423

BibTeX
@article{Guo2024,
  author = {Guo, Jiageng and Jiang, Xinya and Lian, Jing and Li, Huaying and Zhang, Fan and Xie, Jinling and Deng, Jiagang and Hou, Xiaotao and Du, Zhengcai and Hao, Erwei},
  title = {Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2024},
  volume = {12},
  doi = {10.3389/fcell.2024.1431423}
}
Kostenlos starten →